We Study them using trabecular meshwork stem cells, cell reprogramming and pharmacological molecules. We study the disease mechanism of primary and secondary glaucoma and the impact of increased pressure on optic nerve degeneration. We use high throughput transcriptomics and proteomics technology to identify molecular drivers of the pathology and design therapeutic drugs for pre-clinical and clinical studies. Further we will be using stem cells and stem cells derived factors as a treatment option for the severe glaucoma cases.